Table 1. Current status of clinical development of new psychotropic drugs for the treatment of neuropsychiatric disorders.
| Drug | Indication/field | Putative
mechanism |
Phase of
study of action |
Main result
and/or status |
|---|---|---|---|---|
| Pomaglumetad | Schizophrenia | Agonist on
mGlu2/3 |
III | Efficacy only in
schizophrenic patients with a duration of illness <3 years |
| Cariprazine | Schizophrenia | D3/D2/5-HT2B
ligand with a preferential affinity for D3R |
Approved | Approved |
| Cannabidiol | Schizophrenia | CB1 negative
allosteric modulator D2R partial agonist |
II | Ongoing |
| Vortioxetine | Depression | Multimodal
(5-HT receptor agonist/antagonist reuptake inhibitor) |
Approved | Approved |
| Vilazodone | Depression | Multimodal | Approved | Approved |
| Ketamine
(esketamine) |
Depression | NMDA antagonist | III | Ongoing |
| Aducanumab | Alzheimer’s
disease |
Aβ clearance | III | Ongoing |
5-HT, serotonin; Aβ, amyloid beta; CB1, cannabinoid 1; D2R, dopamine 2 receptor; D3R, dopamine 3 receptor; mGlu, metabotropic glutamate; NMDA, N-methyl-D-aspartate